Bausch & Lomb Inc. is nearing a deal to sell itself to drug maker Valeant Pharmaceuticals International Inc. for about $9 billion, according to people familiar with the matter�a surprise move that highlights a resurgence in private-equity deal making after years ...
Bausch & Lomb Said to Be Near $9 Billion Sale to Valeant
New York Times
Report: B+L in talks with Valeant for $9B
Rochester Democrat and Chronicle
Related articles »